HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Abstract
To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.
AuthorsK Linke, R Pazdur, J L Abbruzzese, J A Ajani, R Winn, J E Bradof, K Daugherty, B Levin
JournalInvestigational new drugs (Invest New Drugs) Vol. 9 Issue 4 Pg. 353-6 (Nov 1991) ISSN: 0167-6997 [Print] United States
PMID1804812 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Imides
  • Isoquinolines
  • Naphthalimides
  • Organophosphonates
  • amonafide
  • Adenine
Topics
  • Adenine
  • Adenocarcinoma (drug therapy)
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Drug Evaluation
  • Female
  • Humans
  • Imides
  • Isoquinolines (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Naphthalimides
  • Organophosphonates
  • Pancreatic Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: